iCAD to Present Positive Clinical Data Supporting Use of Xoft System for Early-Stage Breast Cancer and Nonmelanoma Skin Cancer at ASTRO 2016
Company to showcase new technology and host in-booth leading clinician experts to discuss strategies and outcomes in patient care using the Xoft System
NASHUA, NH and BOSTON (Booth #4087) Sept. 26, 2016 - iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, will present updated clinical data supporting use of the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of nonmelanoma skin cancer and early-stage breast cancer at the American Society for Radiation Oncology (ASTRO) meeting in Boston from September 25-28, 2016.
The Company will also showcase the latest electronic brachytherapy technology and host clinician experts at its booth (#4087) to review their experience with the Xoft System.
“The Xoft System offers our customers the versatility to treat multiple cancer types in one integrated system. Our advanced platform technology streamlines the delivery of care, increasing patient satisfaction and positioning the facility as a leader in patient-centric, value-based medicine,” said Ken Ferry, CEO of iCAD.
At the meeting, Alam M. Nisar Syed, MD will present poster #2134, which reflects clinical data from the treatment of 827 women with early-stage breast cancer at 27 hospitals. The findings conclude that IORT with the Xoft System is safe, with low morbidity and excellent-to-good cosmetic results with a low rate of low-grade adverse events.
Ajay Bhatnagar, MD, MBA, will present poster #3750 with data showing that 96 percent of nonmelanoma skin cancer (NMSC) patients surveyed between 32 to 72 months post-treatment with Xoft eBx were satisfied with their clinical and cosmetic treatment outcomes. Dr. Bhatnagar’s research also includes updated data for the treatment of 282 lesions in 187 patients with NMSC, mean age 77 years, showing only three recurrences and good-to-excellent cosmesis at up to five years post-treatment for nearly all patients.
“A growing body of research continues to highlight the Xoft System’s clinical success and drive interest in adopting electronic brachytherapy from customer sites around the world. We are particularly encouraged by customer engagement and increased traction for the skin eBx application, which is further supported by positive clinical data,” added Ferry. “iCAD remains committed to providing innovative, leading-edge radiation therapies that offer valuable solutions to our customers while providing safe and effective treatment for patients.”
Posters are displayed on the exhibit level in Hall C from 10 a.m. to 5 p.m. throughout the meeting. On Monday September 26, poster presenters will be available to discuss their research during the poster viewing session and reception, which will take place in Hall C from 5:30 to 6:45 p.m. EST.
iCAD will also host a series of “Meet the Experts” sessions in the Xoft booth (#4087) from noon to 1 pm on September 25-27. The details regarding the featured clinicians and their scheduled appearances are as follows:
Alam M. Nisar Syed, MD
Medical director, radiation oncology & endocurietherapy,
Memorial Care Cancer, Institute Long Beach Memorial Medical Center
Gary Proulx, MD
Medical director, Exeter Hospital Radiation Oncology
May-Lin Tao, MD, MSPH
Medical director and radiation oncologist, The Center for Radiation Therapy of Beverly Hills
Visitors to booth #4087 will also have the opportunity to demo iCAD’s latest advancements in radiation technology, including the Company’s new Streamlined Module for Advanced Radiation Therapy (SMART) solution and Axxent Hub cloud-based oncology collaboration software solution, which support practices utilizing the Xoft System for the treatment of NMSC. The Company’s new extended-life X-ray source and cervical applicator will also be available for demonstration, as well as its investigational line of general intraoperative radiation therapy (IORT) applicators, which are being shown as works in progress for the treatment of prostate, head/neck, abdominal, and brain cancers.
About Xoft Axxent Electronic Brachytherapy System
The Xoft System is an isotope-free radiation treatment that is FDA cleared, CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. The Xoft System requires only minimal shielding and therefore does not require room redesign or construction investment. Minimal shielding also allows medical personnel to remain in the room with the patient during treatment. The mobility of the Xoft System makes it easy to treat patients at multiple locations and to easily store the system when not in use. The Axxent Hub is a cloud-based oncology collaboration software solution that enables centers to monitor treatment workflow and enhance communication between clinical specialists. Xoft is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit www.xoftinc.com, like us on Facebook or follow us on Twitter at @xofticad.
About iCAD, Inc.
iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit or www.icadmed.com or www.xoftinc.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
For iCAD investor relations:
For iCAD media inquiries:
Berry & Company Public Relations, LLC
Jessica Burns, 212-253-8881
Sales & Services
+1 866 280 2239 toll free
©2017 Xoft®, a subsidiary of iCAD, Inc. All rights reserved. Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are registered trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.